Authors
Iacopo Gianassi, Fiammetta Fossi, Leonardo Caroti, Lorenzo Di Maria, Aida Larti, Giulia Antognoli, Renata Angela Di Pietro, Roberta Cutruzzulà, Giuseppe Cestone, Federica Allegretta, Marco Allinovi, Lino Calogero Cirami
Published in
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. Oct 11, 2026. Epub Oct 11, 2026.
Abstract
Kidney transplant recipients with severe infections often require immunosuppression minimization, increasing the risk of donor-specific antibody (DSA) persistence and antibody-mediated injury. Extracorporeal photopheresis (ECP) may provide immunomodulation while limiting alloimmune activation.
We retrospectively analyzed four kidney transplant recipients with severe infectious complications and concomitant DSAs who required immunosuppression reduction. Clinical scenarios included BK viremia, BK virus nephropathy, Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, and recurrent urinary tract infections. ECP was administered for 12 months as adjunctive therapy.
Following ECP initiation, infectious complications improved or resolved in all patients, with reduction of viral replication when present. DSA levels decreased markedly in all cases. Kidney graft function remained stable throughout follow-up, and no episodes of acute rejection were observed.
ECP may represent a safe and effective immunomodulatory bridge during immunosuppression minimization in kidney transplant recipients with infections and concomitant DSAs.
PMID:
42860265
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0